- Issuer ticker
-
BIOA
- Reported as of
-
17 Apr 2024
- Net transaction value
-
+$54,000
Source evidence
Original filing metadata and source links for verification.
6 source fields
- SEC form
-
4/A - Amendment
- Accepted by SEC
-
10 Mar 2025, 16:11:28 UTC
- Original report date
-
27 Sep 2024
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Dov A. Goldstein as attorney-in-fact
Key filing fact
Rekha Hemrajani filed Form 4/A - Amendment for BioAge Labs, Inc. (BIOA) on 10 Mar 2025.
Key facts
- This page summarizes Rekha Hemrajani's Form 4/A - Amendment filing for BioAge Labs, Inc. (BIOA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Mar 2025, 16:11.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: +$54,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIOA
transaction
Common Stock
Purchase
- Transaction value
- $54,000
- Shares
- +3,000
- Change %
- Price
-
$18.00
- Shares after
- 3,000
- Date
- 27 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
This Form 4 is being amended solely to report the purchase reflected in Table I above, which was inadvertently omitted from the Form 4 filed on September 27, 2024. The Form 4 filed on that date for the reporting person remains otherwise unmodified.